Clinical samples indicate that SLC7A11 levels are higher in HNSCC metastases compared to primary lesions and are associated with poorer prognosis, suggesting that primary lesions (which exhibit lower SLC7A11 levels) are more responsive to ferroptosis therapy, while metastatic lesions may exhibit greater resistance [43,144]. This evidence concerns the gene SLC7A11 and head and neck squamous cell carcinoma.